These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 36309864)
21. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy? Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069 [TBL] [Abstract][Full Text] [Related]
22. Thyroid-associated ophthalmopathy in Iranian patients. Kashkouli MB; Jam S; Sabzvari D; Ketabi N; Azarinia S; SeyedAlinaghi S; Mofid A Acta Med Iran; 2011; 49(9):612-8. PubMed ID: 22052145 [TBL] [Abstract][Full Text] [Related]
23. Establishing the usefulness of the GO-QOL in a UK hospital-treated population with thyroid eye disease in the CIRTED trial. Dietrich A; Taylor P; White P; Wilson V; Uddin J; Lee RWJ; Dayan C; Jackson S; Psychol Health Med; 2018; 23(sup1):1341-1355. PubMed ID: 30092670 [TBL] [Abstract][Full Text] [Related]
24. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy. Edmunds MR; Boelaert K Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164 [TBL] [Abstract][Full Text] [Related]
25. Rituximab for thyroid eye disease. Silkiss RZ; Reier A; Coleman M; Lauer SA Ophthalmic Plast Reconstr Surg; 2010; 26(5):310-4. PubMed ID: 20562667 [TBL] [Abstract][Full Text] [Related]
26. Quality of life in thyroid eye disease: impact of quality of care. Estcourt S; Quinn AG; Vaidya B Eur J Endocrinol; 2011 May; 164(5):649-55. PubMed ID: 21367964 [TBL] [Abstract][Full Text] [Related]
27. Quality of life in patients with thyroid eye disease. Bahmani-Kashkouli M; Pakdel F; Astaraki A; Hashemi M; Honarbakhsh Y; Mirarmandehi B; Jam S J Ophthalmic Vis Res; 2009 Jul; 4(3):164-8. PubMed ID: 23198067 [TBL] [Abstract][Full Text] [Related]
28. Measuring Health-Related Quality of Life in Thyroid Eye Disease. Sharma A; Stan MN; Rootman DB J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S27-S35. PubMed ID: 36346683 [TBL] [Abstract][Full Text] [Related]
29. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501 [TBL] [Abstract][Full Text] [Related]
30. Microbial Keratitis in Thyroid Eye Disease: Clinical Features, Microbiological Profile, and Treatment Outcome. Naik MN; Vasanthapuram VH; Joseph J; Murthy SI Ophthalmic Plast Reconstr Surg; 2019; 35(6):543-548. PubMed ID: 30844912 [TBL] [Abstract][Full Text] [Related]